[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 31 of about 31
1. Barletta JA, Perner S, Iafrate AJ, Yeap BY, Weir BA, Johnson LA, Johnson BE, Meyerson M, Rubin MA, Travis WD, Loda M, Chirieac LR: Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma. J Cell Mol Med; 2009 Aug;13(8B):1977-86
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma.
  • The majority of lung adenocarcinomas express the lineage-specific thyroid transcription factor-1 (TTF-1).
  • We studied 89 consecutive patients with lung adenocarcinomas treated by surgery at Brigham and Women's Hospital between 1997 and 1999 and performed immunohistochemical analysis for TTF-1 expression and fluorescence in situ hybridization for TTF-1 amplification.
  • In patients with lung adenocarcinoma, TTF-1 expression is a predictor of good outcome.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2000 Jan;36(1):8-16 [10632746.001]
  • [Cites] Am J Surg Pathol. 2008 Jun;32(6):810-27 [18391747.001]
  • [Cites] Am J Surg Pathol. 2001 Mar;25(3):363-72 [11224607.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2002 Jun;10(2):103-9 [12051626.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):597-604 [12827614.001]
  • [Cites] J Korean Med Sci. 2003 Aug;18(4):494-500 [12923324.001]
  • [Cites] Hum Pathol. 2004 Jan;35(1):3-7 [14745718.001]
  • [Cites] J Clin Pathol. 2004 Apr;57(4):383-7 [15047742.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3814-22 [15172988.001]
  • [Cites] Cancer. 2004 Oct 1;101(7):1632-8 [15378500.001]
  • [Cites] J Pathol. 2004 Sep;204(1):101-9 [15307143.001]
  • [Cites] J Biol Chem. 1995 Apr 7;270(14):8108-14 [7713914.001]
  • [Cites] Genes Dev. 1996 Jan 1;10(1):60-9 [8557195.001]
  • [Cites] Mod Pathol. 1999 Mar;12(3):318-24 [10102618.001]
  • [Cites] Dev Biol. 1999 May 1;209(1):60-71 [10208743.001]
  • [Cites] Nature. 2005 Jul 7;436(7047):117-22 [16001072.001]
  • [Cites] Br J Cancer. 2005 Aug 22;93(4):450-2 [16052216.001]
  • [Cites] J Natl Compr Canc Netw. 2006 Jul;4(6):548-82 [16813724.001]
  • [Cites] Respirology. 2006 Sep;11(5):533-8 [16916324.001]
  • [Cites] N Engl J Med. 2006 Oct 26;355(17):1763-71 [17065637.001]
  • [Cites] Ann Oncol. 2006 Nov;17(11):1673-6 [16980598.001]
  • [Cites] J Thorac Oncol. 2007 Jul;2(7):581-2 [17607109.001]
  • [Cites] Chest. 2007 Sep;132(3 Suppl):29S-55S [17873159.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16663-8 [17925434.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):893-8 [17982442.001]
  • [Cites] Neoplasia. 2008 Mar;10(3):298-302 [18320074.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Dev Dyn. 2000 Feb;217(2):180-90 [10706142.001]
  • (PMID = 19040416.001).
  • [ISSN] 1582-4934
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P20 CA090578; United States / NCI NIH HHS / CA / R01 CA092824; United States / NCI NIH HHS / CA / CA092824; United States / NCI NIH HHS / CA / R01 CA074386; United States / NCI NIH HHS / CA / CA074386; United States / NCI NIH HHS / CA / CA90578; United States / NCI NIH HHS / CA / CA090578-01A10003; United States / NCI NIH HHS / CA / P50 CA090578; United States / NCI NIH HHS / CA / P20 CA090578-01A10003
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  • [Other-IDs] NLM/ NIHMS120847; NLM/ PMC2830395
  •  go-up   go-down


2. Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, Downie I, Mooney J, Verbeke C, Bellamy C, Keith WN, Oien KA: Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res; 2005 May 15;11(10):3766-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm.
  • PURPOSE: Patients with metastatic adenocarcinoma of unknown origin are a common clinical problem.
  • Data analysis led to a simplified diagnostic panel and decision tree containing 10 markers only: CA125, CDX2, cytokeratins 7 and 20, estrogen receptor, gross cystic disease fluid protein 15, lysozyme, mesothelin, prostate-specific antigen, and thyroid transcription factor 1.
  • CONCLUSIONS: This classification scheme should enable better prediction on biopsy material of the primary site in patients with metastatic adenocarcinoma of unknown origin, leading to improved management and therapy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Neoplasms, Unknown Primary / diagnosis
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Humans. Immunohistochemistry. In Situ Hybridization. Predictive Value of Tests. Sensitivity and Specificity

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15897574.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


3. Lin JD, Chao TC: Follicular thyroid carcinoma: From diagnosis to treatment. Endocr J; 2006 Aug;53(4):441-8
SciCrunch. KEGG: Data: Disease Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular thyroid carcinoma: From diagnosis to treatment.
  • Unusual presentations with bone, lung or soft tissue metastases in initial diagnosis of follicular thyroid carcinoma have been reported occasionally.
  • This implies how difficult it is to diagnosis this type of cancer at the pre-operative or intra-operative stage of treatment.
  • Fine needle aspiration cytology has been shown to be an ineffective method for diagnosing vascular or capsule invasion of follicular thyroid cancer.
  • Clinical application of various gene expressions in thyroid follicular tumors by needle aspiration using in situ hybridization requires further investigation.
  • Although radioactive iodide (131I) has been used as the standard treatment for follicular thyroid carcinoma with distant metastases, the effectiveness of 131I treatment for follicular thyroid carcinoma depends on the differentiation of cancer cells.
  • The possibility of 131I for thyroid remnant ablation replacing a secondary operation for follicular thyroid carcinoma has been debated.
  • Recent studies applied more expressions of sodium iodide symporters to attain the effect of 131I treatment and slow the proliferation of thyroid cancer cell which, in turn, slows the progression of follicular carcinoma.
  • Consensus for the surgical procedures for the specific prognostic risks for follicular thyroid carcinoma is needed.
  • Dedifferentiated, anti-angiogenic, or gene therapies for follicular thyroid cancer with distant metastases or anaplastic transformation comprise the principal directions in future research for this cancer.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / therapy. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / therapy
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biopsy, Fine-Needle. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / pathology. Carcinoma, Papillary / therapy. Diagnostic Imaging. Humans. Iodine Radioisotopes / therapeutic use. Predictive Value of Tests. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16807500.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Iodine Radioisotopes
  • [Number-of-references] 72
  •  go-up   go-down


Advertisement
4. Bai XY, Shen H: [Quantitative analysis of thyroid transcription factor-1 mRNA expressions in primary lung cancer and its metastatic foci]. Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jan;28(1):20-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Quantitative analysis of thyroid transcription factor-1 mRNA expressions in primary lung cancer and its metastatic foci].
  • OBJECTIVE: To observe the expression of thyroid transcription factor-1 (TTF-1) mRNA in human normal adult type II alveolar epithelial cells, embryonic alveolar epithelial cells, and primary lung carcinoma and lymph nodes, thereby exploring the role of TTF-1 mRNA expression in the tumorigenesis, development and metastasis of lung carcinoma.
  • METHODS: TTF-1 mRNA was detected using tissue microarray and in situ hybridization in 1320 different paraffin-embedded tissue specimens.
  • RESULTS: TTF-1 mRNA expression was significantly less intense in embryonic lung than in normal adult lung tissues (P= 0.000), and the two tissues both had significantly greater expression than lung adenocarcinoma, squamous cell carcinoma, small cell carcinoma and large cell carcinoma (P=0.000).
  • Lung adenocarcinoma and small cell carcinoma, with similar expression intensity (P= 0.068), showed stronger expression than squamous cell carcinoma and large cell carcinoma (P=0.000), and squamous cell carcinoma showed stronger expression than large cell carcinoma (P=0.018).
  • In lung adenocarcinoma, squamous cell carcinoma and large cell carcinoma, the intensity of TTF-1 mRNA expression was stronger in lymph node metastases than in the primary foci (P=0.003, P=0.000, P=0.019, respectively).
  • In lung carcinomas, TTF-1 mRNA expression differs between the histological types, high in lung adenocarcinoma and small cell carcinoma and rather low in squamous cell carcinoma and large cell carcinoma.
  • Strong expression of TTF-1 mRNA often indicates high likeliness of lung carcinoma metastasis, and highlights the high metastatic potentials of lung adenocarcinoma, squamous cell carcinoma and large cell carcinoma.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Female. Humans. In Situ Hybridization. Lymphatic Metastasis. Male. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Thyroid Gland / metabolism. Tissue Array Analysis / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18227018.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


5. Ohe C, Sakaida N, Tadokoro C, Fukui H, Asako M, Tomoda K, Uemura Y: Thyroid-like low-grade nasopharyngeal papillary adenocarcinoma: report of two cases. Pathol Int; 2010 Feb;60(2):107-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid-like low-grade nasopharyngeal papillary adenocarcinoma: report of two cases.
  • Thyroid-like low-grade nasopharyngeal papillary adenocarcinoma (LGNPPA) is extremely rare; only four cases have been reported.
  • Herein are presented the case reports of two Japanese male patients with thyroid-like LGNPPA.
  • On immunohistochemistry the tumor cells were positive for cytokeratin (CK)7, CK19, thyroid transcription factor-1 (TTF-1) and vimentin.
  • In situ hybridization for EBV was negative.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Nasopharyngeal Neoplasms / pathology. Nuclear Proteins / biosynthesis. Transcription Factors / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20398195.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


6. Lado-Abeal J, Celestino R, Bravo SB, Garcia-Rendueles ME, de la Calzada J, Castro I, Castro P, Espadinha C, Palos F, Soares P, Alvarez CV, Sobrinho-Simões M, Cameselle-Teijeiro J: Identification of a paired box gene 8-peroxisome proliferator-activated receptor gamma (PAX8-PPARgamma) rearrangement mosaicism in a patient with an autonomous functioning follicular thyroid carcinoma bearing an activating mutation in the TSH receptor. Endocr Relat Cancer; 2010 Sep;17(3):599-610
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a paired box gene 8-peroxisome proliferator-activated receptor gamma (PAX8-PPARgamma) rearrangement mosaicism in a patient with an autonomous functioning follicular thyroid carcinoma bearing an activating mutation in the TSH receptor.
  • Our main objective was to search for mutations in candidate genes and for paired box gene 8-peroxisome proliferator-activated receptor gamma (PAX8-PPARgamma) rearrangement in a well-differentiated angioinvasive follicular thyroid carcinoma (FTC) causing hyperthyroidism.
  • DNA and RNA were extracted from the patient's thyroid tumor, as well as 'normal' thyroid tissue, and from peripheral blood lymphocytes (PBLs) of the patient, her daughter, and two siblings.
  • Nuclear isolation was extracted from the patient's tumor, 'normal' thyroid tissue, PBLs, and uterine leiomyoma tissue.
  • We searched for PAX8-PPARgamma in thyroid, PBL, and uterine leiomyoma samples from the patient and family members.
  • A second rearrangement, PAX8 (exons 1-8)-PPARgamma, was detected in the patient's normal thyroid tissue.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. PPAR gamma / genetics. Paired Box Transcription Factors / genetics. Receptors, Thyrotropin / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Blotting, Western. Female. Gene Rearrangement. Humans. Immunohistochemistry. In Situ Hybridization. Middle Aged. Mosaicism. Mutation

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20427420.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / PAX8 protein, human; 0 / PPAR gamma; 0 / Paired Box Transcription Factors; 0 / Receptors, Thyrotropin
  •  go-up   go-down


7. Algeciras-Schimnich A, Milosevic D, McIver B, Flynn H, Reddi HV, Eberhardt NL, Grebe SK: Evaluation of the PAX8/PPARG translocation in follicular thyroid cancer with a 4-color reverse-transcription PCR assay and automated high-resolution fragment analysis. Clin Chem; 2010 Mar;56(3):391-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the PAX8/PPARG translocation in follicular thyroid cancer with a 4-color reverse-transcription PCR assay and automated high-resolution fragment analysis.
  • BACKGROUND: Molecular testing of thyroid malignancies, in combination with cytologic and histologic examination, is becoming increasingly attractive as a tool for refining traditional morphologic diagnosis.
  • The molecular changes associated with follicular thyroid carcinoma (FTC) are point mutations in RAS oncogenes or the presence of PAX8/PPARG (paired box 8/peroxisome proliferator-activated receptor gamma) rearrangement.
  • RESULTS: The RT-PCR assay is applicable for detecting the various described fusion transcripts of PAX8/PPARG in formalin-fixed, paraffin-embedded thyroid tissue and in fine-needle aspirate biopsy washes from thyroid nodules.
  • A comparison of the RT-PCR assay with dual-fusion fluorescence in situ hybridization showed an overall concordance of 95%.
  • CONCLUSIONS: The introduction of this assay into clinical practice could provide useful information for the diagnosis and possibly for the prognosis and treatment of thyroid cancer in the future.

  • Genetic Alliance. consumer health - Thyroid cancer, follicular.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2008 Sep;93(9):3286-94 [18593772.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Jun;94(6):2092-8 [19318445.001]
  • [Cites] Science. 2000 Aug 25;289(5483):1357-60 [10958784.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Aug;87(8):3947-52 [12161538.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):1016-23 [12170088.001]
  • [Cites] J Clin Endocrinol Metab. 2003 May;88(5):2318-26 [12727991.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jun;88(6):2745-52 [12788883.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4440-5 [12970322.001]
  • [Cites] Oncogene. 2004 Apr 29;23(20):3634-41 [15077183.001]
  • [Cites] Curr Drug Targets Immune Endocr Metabol Disord. 2004 Sep;4(3):221-34 [15379724.001]
  • [Cites] Am J Clin Pathol. 1982 Jan;77(1):20-5 [7055095.001]
  • [Cites] Int J Cancer. 1990 Jan 15;45(1):16-20 [2298499.001]
  • [Cites] Mol Endocrinol. 1990 Oct;4(10):1474-9 [2283998.001]
  • [Cites] Br J Cancer. 1998 Oct;78(8):1012-7 [9792143.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jan;90(1):463-8 [15483076.001]
  • [Cites] J Pathol. 2005 Jul;206(3):305-11 [15852498.001]
  • [Cites] Future Oncol. 2005 Aug;1(4):497-510 [16556026.001]
  • [Cites] Oncogene. 2006 Apr 13;25(16):2304-17 [16331265.001]
  • [Cites] Endocrinology. 2007 Mar;148(3):932-5 [16946003.001]
  • (PMID = 20056739.001).
  • [ISSN] 1530-8561
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA080117; United States / NCI NIH HHS / CA / CA80117
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / PAX8 protein, human; 0 / PPAR gamma; 0 / Paired Box Transcription Factors
  • [Other-IDs] NLM/ NIHMS547600; NLM/ PMC3918957
  •  go-up   go-down


8. Masago K, Asato R, Fujita S, Hirano S, Tamura Y, Kanda T, Mio T, Katakami N, Mishima M, Ito J: Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma. Int J Cancer; 2009 Jun 1;124(11):2744-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma.
  • These mutations have been reported to be almost exclusively found in a pulmonary adenocarcinoma subgroup of NSCLC, with a low frequency in other solid tumors.
  • We describe a patient with advanced-stage papillary thyroid carcinoma (PTC) whose disease had been diagnosed as pulmonary adenocarcinoma at first, and who had a marked response to the EGFR-tyrosine-kinase inhibitor, gefitinib.
  • An in-frame deletion in exon 19 that eliminated 4 amino acids at positions 746 through 750, which is one of the common drug-sensitive mutations in pulmonary adenocarcinoma, and a serine-to-proline substitution at codon 752, were found in a tumor specimen of the patient.
  • We subsequently searched for mutations in the EGFR tyrosine kinase domain in primary tumors from 23 patients with PTC, and drug-sensitive mutations commonly observed in pulmonary adenocarcinoma were found in 7 of these patients.
  • EGFR gene amplification, also considered to be a predictor of response to EGFR-tyrosine-kinase inhibitors, was evaluated by fluorescence in situ hybridization (FISH); however, only 1 FISH-positive tumor was detected.
  • Our data suggest that EGFR-tyrosine-kinase inhibitors may deserve consideration in the treatment of a subset of patients with PTC, just as with pulmonary adenocarcinoma.
  • [MeSH-major] Carcinoma, Papillary / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Cancer. 2012 May 1;130(9):2215-7; author reply 2217-8 [21717456.001]
  • (PMID = 19253367.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


9. Ciampi R, Zhu Z, Nikiforov YE: BRAF copy number gains in thyroid tumors detected by fluorescence in situ hybridization. Endocr Pathol; 2005;16(2):99-105
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BRAF copy number gains in thyroid tumors detected by fluorescence in situ hybridization.
  • Point mutation of the BRAF gene is a common genetic event in papillary thyroid carcinomas.
  • Using fluorescence in situ hybridization with BRAF specific and chromosome 7 centromeric probes, we studied 62 follicular thyroid tumors and 32 papillary carcinomas.
  • We found that numerical changes in BRAF copy number were rare in papillary thyroid carcinomas, while they occurred in 16-45% of follicular tumors of conventional and oncocytic (Hürthle cell) types.
  • By Western blotting, the tumors carrying four copies of the gene revealed higher expression of BRAF protein, suggesting that copy number gain may represent another mechanism of BRAF activation in thyroid tumors.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Follicular / pathology. Carcinoma, Papillary / genetics. Gene Dosage. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Biomarkers, Tumor / analysis. Blotting, Western. Chromosomes, Human, Pair 7 / genetics. DNA Mutational Analysis. Genes, ras / genetics. Genetic Markers. Humans. In Situ Hybridization, Fluorescence

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16199894.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA88041
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Genetic Markers; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


10. Cho Mar K, Eimoto T, Tateyama H, Arai Y, Fujiyoshi Y, Hamaguchi M: Expression of matrix metalloproteinases in benign and malignant follicular thyroid lesions. Histopathology; 2006 Feb;48(3):286-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of matrix metalloproteinases in benign and malignant follicular thyroid lesions.
  • AIMS: To examine expression of matrix metalloproteinases (MMPs) and related proteins in follicular thyroid lesions (FTLs) and to determine their usefulness for differential diagnosis of FTLs, particularly between minimally invasive carcinoma and adenoma.
  • In-situ hybridization of MMP-2 and MMP-7 mRNA in selected cases demonstrated the expression of these enzymes in the tumour cells as well as in some stromal cells.
  • [MeSH-major] Adenocarcinoma, Follicular / chemistry. Adenoma / chemistry. Matrix Metalloproteinases / analysis. Thyroid Neoplasms / chemistry
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Immunohistochemistry. In Situ Hybridization. Male. Matrix Metalloproteinase 2 / analysis. Matrix Metalloproteinase 2 / genetics. Matrix Metalloproteinase 7 / analysis. Matrix Metalloproteinase 7 / genetics. Middle Aged. Neoplasm Invasiveness. RNA, Messenger / analysis. Thyroid Gland / chemistry. Thyroid Gland / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16430475.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 3.4.24.- / Matrix Metalloproteinases; EC 3.4.24.23 / Matrix Metalloproteinase 7; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


11. Anagnostou VK, Syrigos KN, Bepler G, Homer RJ, Rimm DL: Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J Clin Oncol; 2009 Jan 10;27(2):271-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma.
  • PURPOSE: Thyroid transcription factor 1 (TTF1) is a transcription factor that regulates the expression of multiple genes involved in lung development.
  • PATIENTS AND METHODS: Automated quantitative analysis, a fluorescent-based method for analysis of in situ protein expression, was used to assess a series of cell lines to find the threshold of detection of TTF1 expression.
  • Survival analysis showed that patients with stage I adenocarcinoma with TTF1 expression had a longer median overall survival than those without expression (n = 43, 44.3 v 26.2 months, P = .05 for the first cohort; n = 87; 49.7 v 38.5 months, P = .03 for the second cohort) Multivariate analysis revealed an independent lower risk of death for patients with stage I adenocarcinoma with TTF1-expressing tumors (hazard ratio = 0.479, 95% CI, 0.235 to 0.977; P = .043).
  • CONCLUSION: TTF1 expression defines a subgroup of patients with a favorable outcome and may be useful for prognostic stratification of patients with stage I lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / biosynthesis. Lung Neoplasms / metabolism. Nuclear Proteins / biosynthesis. Transcription Factors / biosynthesis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19064983.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


12. French CA, Fletcher JA, Cibas ES, Caulfield C, Allard P, Kroll TG: Molecular detection of PPAR gamma rearrangements and thyroid carcinoma in preoperative fine-needle aspiration biopsies. Endocr Pathol; 2008;19(3):166-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular detection of PPAR gamma rearrangements and thyroid carcinoma in preoperative fine-needle aspiration biopsies.
  • The pathologic diagnosis of thyroid follicular tumors is difficult, particularly in preoperative fine-needle aspiration biopsies.
  • To investigate whether the molecular diagnosis of PPAR gamma rearrangements can detect thyroid carcinomas in fine-needle aspiration biopsies, we performed interphase fluorescence in situ hybridization on 24 thyroid fine-needle aspiration and 17 follow-up thyroidectomy specimens.
  • Two of the 24 fine-needle aspiration biopsies contained PPAR gamma rearrangements, and both were diagnosed suggestive of a thyroid follicular neoplasm by cytology.
  • The two corresponding thyroidectomies each contained PPAR gamma rearrangements in all tumor cells and, both were diagnosed follicular-patterned thyroid carcinomas-one a follicular carcinoma and the other a follicular variant of papillary carcinoma, the latter by majority of expert endocrine pathologists.
  • Our experiments demonstrate that PPAR gamma rearrangements can detect a subset of follicular-patterned thyroid carcinomas in preoperative thyroid fine-needle aspiration biopsies.
  • The ultimate utility of mutations such as PPAR gamma rearrangements in diagnosis of thyroid carcinoma must be proven by direct correlation of mutation status with thyroid tumor biology and not just with thyroid tumor morphology, a subjective and imprecise marker of clinical behavior.
  • The application of specific mutations to preoperative diagnosis of thyroid carcinoma is predicted to improve the accuracy and reduce the costs of treating patients with thyroid tumors.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Biomarkers, Tumor / genetics. PPAR gamma / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy, Fine-Needle. Female. Gene Rearrangement. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Endocr Pathol. 2008 Winter;19(4):299
  • (PMID = 18688583.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA75425
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PPAR gamma
  •  go-up   go-down


13. Striebel JM, Dacic S, Yousem SA: Gross cystic disease fluid protein-(GCDFP-15): expression in primary lung adenocarcinoma. Am J Surg Pathol; 2008 Mar;32(3):426-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gross cystic disease fluid protein-(GCDFP-15): expression in primary lung adenocarcinoma.
  • A total of 211 cases of primary lung adenocarcinoma were tested for expression of gross cystic disease fluid protein-15 (GCDFP-15) and only 11 cases (5.2%) were positive.
  • GCDFP-15 was expressed in conjunction with thyroid transcription factor-1 in 81% of cases and synaptophysin was seen in 65%.
  • This report details the first 11 cases of pulmonary adenocarcinoma to express GCDFP-15 and their distinctive morphology with frequent mucin production and coexpression of thyroid transcription factor-1 and synaptophysin.
  • [MeSH-major] Adenocarcinoma / chemistry. Adenocarcinoma / pathology. Carrier Proteins / analysis. Glycoproteins / analysis. Lung Neoplasms / chemistry. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Papillary / chemistry. Adenocarcinoma, Papillary / pathology. Aged. Female. Histocytochemistry. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Mucins / analysis. Nuclear Proteins / analysis. Synaptophysin / analysis. Transcription Factors / analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18300807.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Glycoproteins; 0 / Mucins; 0 / Nuclear Proteins; 0 / PIP protein, human; 0 / Synaptophysin; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


14. Lindholm PM, Soini Y, Myllärniemi M, Knuutila S, Heikinheimo M, Kinnula VL, Salmenkivi K: Expression of GATA-6 transcription factor in pleural malignant mesothelioma and metastatic pulmonary adenocarcinoma. J Clin Pathol; 2009 Apr;62(4):339-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of GATA-6 transcription factor in pleural malignant mesothelioma and metastatic pulmonary adenocarcinoma.
  • New markers for the prediction of prognosis in MM and in pulmonary adenocarcinoma of the pleura are valuable.
  • Expression of GATA-6 was examined in relation to thyroid transcription factor-1 expression, survival, proliferation and apoptosis.
  • RESULTS: Nuclear immunoreactivity for GATA-6 was stronger and more frequent in MM than in metastatic pleural adenocarcinoma.
  • GATA-6 was not associated with spontaneous proliferation or apoptosis of the tumour cells in situ.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Apoptosis. Cell Proliferation. Humans. Immunoenzyme Techniques. In Situ Nick-End Labeling / methods. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Neoplasm Proteins / metabolism. Prognosis. Survival Analysis. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19060016.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GATA6 Transcription Factor; 0 / Neoplasm Proteins
  •  go-up   go-down


15. Drieschner N, Belge G, Rippe V, Meiboom M, Loeschke S, Bullerdiek J: Evidence for a 3p25 breakpoint hot spot region in thyroid tumors of follicular origin. Thyroid; 2006 Nov;16(11):1091-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence for a 3p25 breakpoint hot spot region in thyroid tumors of follicular origin.
  • Epithelial tumors of the thyroid are cytogenetically well-investigated tumors.
  • Recently, we have been able to describe the involvement of a novel gene called THADA in benign thyroid lesions with 2p21 rearrangements.
  • Other fusion genes found in thyroid lesions are RET/PTC and PAX8/PPAR(gamma).
  • The latter occurs in follicular thyroid carcinomas with a t(2;3)(q13;p25).
  • Here we present molecular-cytogenetic and cytogenetic investigations on a follicular thyroid adenoma with a t(2;20;3)(p21;q11.2; p25).
  • We used BAC clones containing the genomic sequence of PPARgamma for fluorescence in situ hybridization to confirm the localization of the breakpoint within intron 2 of PPAR(gamma) .
  • Our findings suggest that the close surrounding of PPAR(gamma) is a breakpoint hot spot region, leading to recurrent alterations of this gene in thyroid tumors of follicular origin including carcinomas as well as adenomas with or without involvement of PAX8.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Chromosome Breakage. Neoplasm Proteins / genetics. PPAR gamma / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Alternative Splicing. Chromosome Mapping. Chromosomes, Human, Pair 2. Chromosomes, Human, Pair 20. Chromosomes, Human, Pair 3. Female. Gene Rearrangement. Humans. In Situ Hybridization, Fluorescence. Middle Aged

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17123335.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / PPAR gamma; 0 / THADA protein, human
  •  go-up   go-down


16. Castro P, Roque L, Magalhães J, Sobrinho-Simões M: A subset of the follicular variant of papillary thyroid carcinoma harbors the PAX8-PPARgamma translocation. Int J Surg Pathol; 2005 Jul;13(3):235-8
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A subset of the follicular variant of papillary thyroid carcinoma harbors the PAX8-PPARgamma translocation.
  • The occurrence of the PAX8-PPARgamma fusion gene is thought to be restricted to follicular tumors (adenomas and carcinomas) of the thyroid (FTA and FTC).
  • Using interphase fluorescent in situ hybridization (FISH), together with recombinant tissue-type polymerase chain reaction (RT-PCR) and immunohistochemistry, we detected the PAX8-PPARgamma translocation in 4 of 8 cases of the follicular variant of papillary thyroid carcinoma (FVPTC) exclusively or almost exclusively (>95%) composed of follicles.
  • Our findings show that follicular thyroid carcinoma (PTC) may also harbor the PAX8-PPARgamma fusion gene and indicate that a subset of FVPTC shares some molecular features of FTA and FTC.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Papillary / genetics. DNA-Binding Proteins / genetics. Nuclear Proteins / genetics. Oncogene Proteins, Fusion / genetics. PPAR gamma / genetics. Thyroid Neoplasms / genetics. Trans-Activators / genetics
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Humans. Immunoenzyme Techniques. Immunohistochemistry. In Situ Hybridization, Fluorescence. PAX8 Transcription Factor. Paired Box Transcription Factors. RNA, Messenger / metabolism. RNA, Neoplasm / analysis. Reverse Transcriptase Polymerase Chain Reaction. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16086077.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 0 / PAX8 Transcription Factor; 0 / PAX8 protein, human; 0 / PPAR gamma; 0 / Paired Box Transcription Factors; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Trans-Activators
  •  go-up   go-down


17. Coyne C, Nikiforov YE: RAS mutation-positive follicular variant of papillary thyroid carcinoma arising in a struma ovarii. Endocr Pathol; 2010 Jun;21(2):144-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RAS mutation-positive follicular variant of papillary thyroid carcinoma arising in a struma ovarii.
  • Struma ovarii is an ovarian mature teratoma composed exclusively or predominantly of thyroid tissue.
  • Malignant transformation of struma ovarii is rare and poorly understood, although this process is thought to be similar to carcinogenesis in malignant tumors of differentiated thyroid tissue originating in the thyroid gland.
  • Genetic alterations in the mitogen-activated protein kinase pathway, including mutations of BRAF, RAS, and RET genes, have been implicated in the development of differentiated thyroid carcinoma arising in the thyroid gland.
  • She proceeded to ovarian cystectomy post-delivery, with pathologic examination detecting a papillary thyroid carcinoma, follicular variant, arising in a cystic teratoma.
  • It provides evidence that tumors developing in this setting involve molecular mechanisms similar to those implicated in tumors developing in the thyroid gland.
  • [MeSH-major] Adenocarcinoma, Papillary / genetics. Neoplasms, Multiple Primary / genetics. Ovarian Neoplasms / genetics. Struma Ovarii / genetics. Thyroid Neoplasms / genetics. ras Proteins / genetics
  • [MeSH-minor] Adult. Female. Humans. In Situ Hybridization, Fluorescence. Mutation. Proto-Oncogene Proteins B-raf / genetics. Proto-Oncogene Proteins c-ret / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19898969.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


18. Canchola AJ, Horn-Ross PL, Purdie DM: Risk of second primary malignancies in women with papillary thyroid cancer. Am J Epidemiol; 2006 Mar 15;163(6):521-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of second primary malignancies in women with papillary thyroid cancer.
  • Second malignancies in women diagnosed with thyroid cancer are of concern given the young average age at diagnosis and excellent survival.
  • Data from the California Cancer Registry were used to evaluate the risk of second primary cancers among a retrospective population-based cohort of 10,932 women diagnosed with papillary thyroid cancer between 1988 and 1999.
  • Follow-up was calculated from 2 months until the diagnosis of a second primary cancer, death, loss to follow-up, or December 31, 1999, whichever occurred first.
  • An excess of in situ breast cancer (SIR = 1.6, 95% CI: 1.0, 2.4), kidney cancer (SIR = 3.9, 95% CI: 2.2, 6.3), and melanoma (SIR = 2.1, 95% CI: 1.3, 3.2) limited to the first 5 years after diagnosis was observed.
  • Women with papillary thyroid cancer are at increased risk of in situ, but not invasive, breast cancer, kidney cancer, and melanoma.
  • [MeSH-major] Adenocarcinoma, Papillary / epidemiology. Breast Neoplasms / epidemiology. Kidney Neoplasms / epidemiology. Melanoma / epidemiology. Neoplasms, Second Primary / epidemiology. Thyroid Neoplasms / epidemiology


19. Levy MJ, Clain JE, Clayton A, Halling KC, Kipp BR, Rajan E, Roberts LR, Root RM, Sebo TJ, Topazian MD, Wang KK, Wiersema MJ, Gores GJ: Preliminary experience comparing routine cytology results with the composite results of digital image analysis and fluorescence in situ hybridization in patients undergoing EUS-guided FNA. Gastrointest Endosc; 2007 Sep;66(3):483-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary experience comparing routine cytology results with the composite results of digital image analysis and fluorescence in situ hybridization in patients undergoing EUS-guided FNA.
  • BACKGROUND: Studies indicate enhanced diagnostic accuracy for digital image analysis (DIA) and fluorescence in situ hybridization (FISH) versus routine cytology examination (RC) when biliary strictures are evaluated.
  • The final diagnosis was based on strict cytopathologic and imaging criteria and 12-month follow-up.
  • PATIENTS: A total of 39 patients were enrolled in whom each diagnostic test was performed on samples from 42 sites to evaluate lymphadenopathy (n=19), pancreatic mass (n=19), esophageal or gastric wall mass (n=3), and thyroid mass (n=1).
  • RESULTS: Malignancy was diagnosed in 30 of 42 patients, including esophageal squamous cell carcinoma, esophageal adenocarcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma, pancreatic mucinous cystic neoplasia, intraductal papillary mucinous neoplasia, metastatic forearm sarcoma, small cell and non-small cell lung cancer, thyroid carcinoma, malignant GI stromal tumor, melanoma, adenocarcinoma of unknown primary, and lymphoma.
  • [MeSH-major] Biopsy, Fine-Needle. Endosonography. Esophageal Neoplasms / pathology. Image Processing, Computer-Assisted. In Situ Hybridization, Fluorescence. Lymphatic Metastasis / pathology. Pancreatic Neoplasms / pathology. Stomach Neoplasms / pathology. Thyroid Neoplasms / pathology


20. Sterlacci W, Verdorfer I, Gabriel M, Mikuz G: Thyroid follicular carcinoma-like renal tumor: a case report with morphologic, immunophenotypic, cytogenetic, and scintigraphic studies. Virchows Arch; 2008 Jan;452(1):91-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid follicular carcinoma-like renal tumor: a case report with morphologic, immunophenotypic, cytogenetic, and scintigraphic studies.
  • In this report, a rare renal tumor that morphologically resembles a thyroid follicular carcinoma is described.
  • CD-10, CD-117, thyroid transcription factor-1, and thyreoglobulin remained completely negative.
  • Chromosomal losses of 1, 3, 7, 9p21, 12, 17, and X were detected by fluorescence in situ hybridization.
  • Scintigraphs showed an inconspicuous thyroid gland and no extrathyroidal pathological accumulations, making metastatic spread to the kidney highly unlikely.
  • To our knowledge, this is the second fully documented case of a thyroid follicular carcinoma-like renal tumor.
  • [MeSH-major] Adenocarcinoma, Follicular / secondary. Kidney Neoplasms / secondary. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Chromosome Deletion. Cytogenetics. Diagnosis, Differential. Disease-Free Survival. Female. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Nephrectomy. Radionuclide Imaging. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Virchows Arch. 2009 Jun;454(6):717-8 [19449026.001]
  • [ErratumIn] Virchows Arch. 2008 Apr;452(4):471. William, Sterlacci [corrected to Sterlacci, William]; Irmgard, Verdorfer [corrected to Verdorfer, Irmgard]; Michael, Gabriel [corrected to Gabriel, Michael]; Gregor, Mikuz [corrected to Mikuz, Gregor]
  • (PMID = 17704942.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


21. Sadow PM, Heinrich MC, Corless CL, Fletcher JA, Nosé V: Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas. Endocr Pathol; 2010 Jun;21(2):73-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas.
  • Dominant nodules within Hashimoto thyroiditis (HT) may present with unique morphological features that overlap with but are not diagnostic of papillary thyroid carcinoma (PTC).
  • Activating BRAF point mutations, RAS aberrations, and RET rearrangements are mutually exclusive events in the oncogenesis of papillary thyroid carcinoma, and RET rearrangements have been previously described in dominant nodules of HT.
  • Of ten cases with diagnostic concomitant or incidental papillary carcinoma, three had a V600E point mutation in BRAF, and one case had a BRAF exon 15 deletion (600-604E), while the dominant nodules were negative for mutation, supporting the notion that dominant nodules are neither malignant nor precursor lesions, and strict histological, clinical, and molecular criteria must be met for the diagnosis of papillary thyroid carcinoma.
  • [MeSH-major] Adenocarcinoma, Papillary / genetics. Adenocarcinoma, Papillary / pathology. Hashimoto Disease / genetics. Hashimoto Disease / pathology. Thyroid Neoplasms / genetics. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Gene Rearrangement. Genotype. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Mutation. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins B-raf / genetics. Proto-Oncogene Proteins c-ret / genetics. Proto-Oncogene Proteins p21(ras) / genetics. Receptors, Cell Surface / genetics. Reverse Transcriptase Polymerase Chain Reaction. ras Proteins / genetics

  • Genetic Alliance. consumer health - Hashimoto's Disease.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20012784.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / Receptors, Cell Surface; 0 / patched receptors; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / HRAS protein, human; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras); EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


22. Achille M, Boukheris H, Caillou B, Talbot M, de Vathaire F, Sabatier L, Desmaze C, Schlumberger M, Soria JC: Expression of cell cycle biomarkers and telomere length in papillary thyroid carcinoma: a comparative study between radiation-associated and spontaneous cancers. Am J Clin Oncol; 2009 Feb;32(1):1-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cell cycle biomarkers and telomere length in papillary thyroid carcinoma: a comparative study between radiation-associated and spontaneous cancers.
  • OBJECTIVE: Radiation exposure during childhood is the only well-established risk factor for papillary thyroid carcinoma (PTC).
  • The expression of cell cycle regulators was studied using immunohistochemistry; telomere length heterogeneity was studied using in situ hybridization in a subset of 16 formalin-fixed samples (8 radiation-induced and 8 sporadic PTCs).
  • [MeSH-major] Carcinoma, Papillary / metabolism. Cell Cycle Proteins / metabolism. Neoplasms, Radiation-Induced / metabolism. Telomere / metabolism. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Case-Control Studies. Child. Child, Preschool. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Infant. Male. Middle Aged. Prognosis. Tissue Array Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19194115.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins
  •  go-up   go-down


23. Duprez R, Lebas P, Marc OS, Mongeois E, Emy P, Michenet P: Preoperative US-guided hook-needle insertion in recurrent lymph nodes of papillary thyroid cancer: a help for the surgeon. Eur J Radiol; 2010 Jan;73(1):40-2
MedlinePlus Health Information. consumer health - Ultrasound.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative US-guided hook-needle insertion in recurrent lymph nodes of papillary thyroid cancer: a help for the surgeon.
  • OBJECTIVE: The objective of this study is to investigate whether preoperative ultrasound guided insertion of a hook-needle is useful in reoperations for cervical recurrent lymph node metastases of papillary thyroid cancer.
  • PATIENTS AND METHODS: 8 patients with operated papillary thyroid cancer were included in this study.
  • These lymph nodes were identified by ultrasound imaging and their metastatic nature was confirmed by fine needle aspiration cytology and measurement of in situ thyroglobulin.
  • [MeSH-major] Adenocarcinoma, Papillary / diagnosis. Adenocarcinoma, Papillary / secondary. Biopsy, Needle / methods. Neoplasm Recurrence, Local / prevention & control. Sentinel Lymph Node Biopsy / methods. Thyroid Neoplasms / diagnosis. Ultrasonography / methods

  • Genetic Alliance. consumer health - Thyroid cancer, papillary.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19036543.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


24. Bai XY, Shen H: Mutational analysis of thyroid transcription factor-1 gene (TTF-1) in lung carcinomas. In Vitro Cell Dev Biol Anim; 2008 Jan-Feb;44(1-2):17-25
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutational analysis of thyroid transcription factor-1 gene (TTF-1) in lung carcinomas.
  • We studied the expression and mutation of thyroid transcription factor-1 (TTF-1) gene in 92 cases of lung carcinomas comprised of lung adenocarcinoma (36 cases), squamous cell lung carcinoma (42 cases), small cell lung carcinoma (8 cases), and large cell lung carcinoma (6 cases) to investigate whether TTF-1 gene mutation predisposed to the development of lung cancer.
  • [MeSH-minor] Base Sequence. DNA Mutational Analysis. Humans. In Situ Hybridization. Lung / cytology. Lung / metabolism. Lung / pathology. Polymorphism, Single-Stranded Conformational

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18071837.001).
  • [ISSN] 1071-2690
  • [Journal-full-title] In vitro cellular & developmental biology. Animal
  • [ISO-abbreviation] In Vitro Cell. Dev. Biol. Anim.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


25. Yatabe Y, Takahashi T, Mitsudomi T: Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. Cancer Res; 2008 Apr 1;68(7):2106-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have reported evidence implicating mutation specifically in the "terminal respiratory unit" type of adenocarcinoma, which is characterized by expression of thyroid transcription factor 1, a lineage marker of peripheral airway cells.
  • However, little is known about the role of gene amplification in the molecular progression of lung adenocarcinoma.
  • Relative copy number of the gene was analyzed using Taq Man-based gene dosage analysis and fluorescent in situ hybridization technique.
  • We also examined 17 precursor lesions and 21 in situ lung adenocarcinomas, and found that only one in situ carcinoma harbored gene amplification.
  • Taken together, our results show that mutation occurs early in the development of lung adenocarcinoma, and that amplification may be acquired in association with tumor progression.
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / genetics. Adenocarcinoma / pathology. Carcinoma, Adenosquamous / enzymology. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / pathology. Disease Progression. Female. Humans. In Situ Hybridization, Fluorescence. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18381415.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


26. Tanaka H, Yanagisawa K, Shinjo K, Taguchi A, Maeno K, Tomida S, Shimada Y, Osada H, Kosaka T, Matsubara H, Mitsudomi T, Sekido Y, Tanimoto M, Yatabe Y, Takahashi T: Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res; 2007 Jul 1;67(13):6007-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We show that a subset of lung adenocarcinoma cell lines expressing TTF-1, which presumably represent those derived from the TRU lineage, exhibit marked dependence on the persistent expression of TTF-1.
  • The inhibition of TTF-1 by RNA interference (RNAi) significantly and specifically induced growth inhibition and apoptosis in these adenocarcinoma cell lines.
  • [MeSH-major] Adenocarcinoma / pathology. DNA-Binding Proteins / physiology. Gene Expression Regulation, Neoplastic. Lung / pathology. Lung Neoplasms / pathology. Nuclear Proteins / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Apoptosis. Carcinoma, Non-Small-Cell Lung / pathology. Cell Line, Tumor. Cell Lineage. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. RNA Interference. Stem Cells

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17616654.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


27. Kajiwara H, Kumaki N, Hirabayashi K, Miyazawa M, Nakamura N, Hirasawa T, Muramatsu T, Mikami M, Yasuda M, Osamura RY: A case of oncocytic carcinoma of the endometrium. Arch Gynecol Obstet; 2009 May;279(5):733-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report an unusual case of endometrial adenocarcinoma in a 80-year-old woman who underwent mastectomy for breast cancer at 68 years of age.
  • Components of the carcinoma were focally observed in situ.
  • They were positive for antimitochondrial antigen and thyroid transcription factor-1.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Neoplasms, Second Primary / pathology

  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18795309.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


28. Kuuselo R, Simon R, Karhu R, Tennstedt P, Marx AH, Izbicki JR, Yekebas E, Sauter G, Kallioniemi A: 19q13 amplification is associated with high grade and stage in pancreatic cancer. Genes Chromosomes Cancer; 2010 Jun;49(6):569-75
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We used fluorescence in situ hybridization on tissue microarrays containing 357 primary pancreatic tumors, 151 metastases, and 24 local recurrences as well as 120 cancer cell lines from various tissues to establish the frequency of the 19q13 amplification and to find potential correlations to clinical parameters including patient survival.
  • Copy number increases were found in 12.2% of the primary pancreatic tumors and 9.3% of the cell lines, including those derived from bladder, colorectal, ovarian, and thyroid carcinomas.
  • Our findings revealed recurrent 19q13 amplification in pancreatic cancer and involvement of the same locus as in bladder, colorectal, ovarian, and thyroid carcinomas.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • [Cites] Genes Chromosomes Cancer. 2009 Apr;48(4):289-309 [19105235.001]
  • [Cites] PLoS Genet. 2008 May;4(5):e1000081 [18535672.001]
  • [Cites] Mod Pathol. 2009 Apr;22(4):499-507 [19151661.001]
  • [Cites] Cancer Biol Ther. 2008 Nov;7(11):1793-802 [18836286.001]
  • [Cites] Am J Pathol. 2000 Sep;157(3):787-94 [10980118.001]
  • [Cites] Cancer Lett. 2001 Jun 26;167(2):115-23 [11369131.001]
  • [Cites] Cytometry. 2001 Oct 1;45(2):83-6 [11590619.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1720-30 [12060609.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Dec;35(4):353-8 [12378529.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7157-61 [12499249.001]
  • [Cites] Breast Cancer Res Treat. 2003 Apr;78(3):337-45 [12755492.001]
  • [Cites] BMC Cancer. 2004 Feb 6;4:5 [15018632.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9067-72 [15199222.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4428-33 [15231651.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Jul;84(14):5034-7 [3037531.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 15;89(10):4285-9 [1350088.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9267-71 [1409633.001]
  • [Cites] Int J Cancer. 1993 Sep 30;55(3):422-8 [8375927.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2156-60 [8134364.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7):1801-6 [8137295.001]
  • [Cites] Int J Cancer. 1995 Aug 22;64(4):280-5 [7657393.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Mar;87(1):55-62 [8646743.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2383-90 [9796969.001]
  • [Cites] Am J Clin Pathol. 1999 Jul;112(1 Suppl 1):S11-8 [10396297.001]
  • [Cites] Neoplasia. 2004 Sep-Oct;6(5):432-9 [15548351.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8534-40 [15574759.001]
  • [Cites] Oncogene. 2005 Mar 3;24(10):1794-801 [15688027.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Sep;44(1):37-51 [15929091.001]
  • [Cites] Neoplasia. 2005 Jun;7(6):556-62 [16036106.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8235-42 [16322280.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4149-58 [16618736.001]
  • [Cites] Oncogene. 2006 Jun 1;25(23):3247-57 [16491129.001]
  • [Cites] Trends Genet. 2006 Aug;22(8):447-55 [16787682.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):1943-9 [17332321.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Apr;48(4):330-9 [19145645.001]
  • (PMID = 20232484.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA109552-01A1; United States / NCI NIH HHS / CA / P01 CA109552; United States / NCI NIH HHS / CA / P01 CA109552-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS189142; NLM/ PMC2855495
  •  go-up   go-down


29. Perner S, Wagner PL, Soltermann A, LaFargue C, Tischler V, Weir BA, Weder W, Meyerson M, Giordano TJ, Moch H, Rubin MA: TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival. J Pathol; 2009 Jan;217(1):65-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Aged. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Female. Gene Amplification. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis. Thyroid Neoplasms / genetics. Thyroid Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18932182.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / TTF1 protein, human
  •  go-up   go-down


30. Barnett BP, Sheth S, Ali SZ: Cytopathologic analysis of paratracheal masses: a study of 737 cases with clinicoradiologic correlation. Acta Cytol; 2009 Nov-Dec;53(6):672-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the malignant cases, 45 (73%) were metastatic tumors: adenocarcinoma (ACA) 19, small cell carcinoma 12, squamous cell carcinoma (SQCC) 11 and other tumors, from lung 34, esophagus 4 and other sites.
  • Malignant neoplasms from local spread included lung non-small cell carcinoma 6, SQCC 3 and ACA 3, papillary thyroid carcinoma 3 and other 2.
  • The most common diagnosis is a malignant tumor (60%), with metastatic carcinoma (73%) the most common neoplasm (lung ACA the most common primary source).
  • Ancillary studies (immunoctyochemistry, fluorescence in situ hybridization and electron microscopy) were helpful and provided definitive diagnosis in 30% of the initially nondiagnostic FNA samples.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20014557.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Grant] United States / Howard Hughes Medical Institute / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


31. Ohe C, Kuroda N, Pan CC, Yang XJ, Hes O, Michal M, Uehara H, Hamada S, Kirime S, Senzaki H: A unique renal cell carcinoma with features of papillary renal cell carcinoma and thyroid-like carcinoma: a morphological, immunohistochemical and genetic study. Histopathology; 2010 Sep;57(3):494-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A unique renal cell carcinoma with features of papillary renal cell carcinoma and thyroid-like carcinoma: a morphological, immunohistochemical and genetic study.
  • [MeSH-minor] Adenocarcinoma, Follicular. Carcinoma / pathology. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Thyroid Neoplasms / genetics. Thyroid Neoplasms / metabolism. Thyroid Neoplasms / pathology






Advertisement